mTOR inhibitor
Sirolimus (Oral microdose)
White capsule contents
Typical Strength
per prescriber
Formulations
1 compounds
Formula
C₅₁H₇₉NO₁₃
Mol. Weight
914.17 g/mol
How It Works
Mechanism of action
mTOR pathway inhibitor studied in longevity research for its effects on cellular senescence and autophagy. Longevity use is off-label and investigational; dosing and monitoring are prescriber-directed.
Did you know?
Sirolimus (rapamycin) was discovered in a soil bacterium on Easter Island — its name derives from Rapa Nui, the island's native name.
What compounding can change
When Sirolimus (Oral microdose) is compounded for one patient, your prescriber can choose the concentration, combine it with other ingredients, and pick the base. Commercial products come in fixed strengths and bases.
Safety Considerations
Available In
Formulations with Sirolimus (Oral microdose)
Please note: Compounded medications require a prescription from a licensed prescriber for an individual patient. Compounded medications are not FDA-approved. The FDA does not review them for safety, effectiveness or quality. A compounded medication is not the same as, or a generic version of, any FDA-approved drug. This page is general information, not medical advice. Your prescriber decides whether a treatment is right for you and sets the final ingredients, strength and dosage form.